Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 9/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 8/20 | 0.53 |
| ▸ | HTR6 | P50406 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3232114 | 0.84 | CNR1 (0.43) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3234769 | 0.83 | ALDH1A1 (0.51) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3236666 | 0.82 | ALDH1A1 (0.47) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL13423350 | 0.81 | KCNH2 (0.53) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3237113 | 0.81 | ALDH1A1 (0.54) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3235779 | 0.81 | CNR1 (0.56) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3231877 | 0.78 | MAPK1 (0.51) | ALDH1A1GAA | |
| SCHEMBL23400074 | 0.76 | CACNA1H (0.47) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL3300740 | 0.75 | KCNH2 (0.60) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 | |
| SCHEMBL17259259 | 0.75 | KCNH2 (0.60) | KCNH2CACNA1HCACNA1GHTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101663289-B | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RES INST CHEM TECH | 2014-07-23 | — | — | CN | disclosed |
| US-8372844-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-02-12 | — | — | US | disclosed |
| US-20120209001-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-16 | — | — | US | disclosed |
| US-8236806-B2 | Piperazinyl-propyl-pyrazole derivatives as dopamine D4 receptor antagonists, and pharmaceutical compositions containing the same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-08-07 | — | — | US | disclosed |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-03-11 | — | — | US | disclosed |
| CN-101663289-A | Piperazinyl-propyl-pyrazole derivatives and the pharmaceutical composition that comprises them as dopamine d 4 receptor antagonists | KOREA RES INST CHEM TECH | 2010-03-03 | — | — | CN | disclosed |
| WO-2008108517-A2 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209001-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | KCNH2 1834/4885CACNA1H 2693/4885CACNA1G 2726/4885 |
| US-20100063286-A1 | PIPERAZINYL-PROPYL-PYRAZOLE DERIVATIVES AS DOPAMINE D4 RECEPTOR ANTAGONISTS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | HTR3B, HTR3C, HTR3D | KCNH2 1834/4885CACNA1H 2693/4885CACNA1G 2726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.